Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008537 | 0.84 | PPARA (0.47) | MRGPRX4TSHRTDP1MAOBLTB4R | |
| SCHEMBL957978 | 0.83 | SLC22A12 (0.68) | SLC22A12PLA2G4BMAOBLTB4RLTB4R2 | |
| SCHEMBL1760801 | 0.81 | PPARD (0.49) | SLC22A12GAATSHRNFKB1TDP1 | |
| SCHEMBL954459 | 0.81 | NR4A2 (0.66) | ALDH1A1TSHRMAOBLTB4RLTB4R2 | |
| SCHEMBL229067 | 0.80 | PTGS1 (0.67) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL29824310 | 0.80 | PTGS1 (0.67) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL955741 | 0.80 | PPARD (0.48) | SLC22A12MRGPRX4ALDH1A1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL8693464 | 0.79 | CTBP2 (0.65) | ALDH1A1CTBP2LMNAPTGS1AKR1C3 | |
| SCHEMBL8218805 | 0.79 | CTBP2 (0.65) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL3901473 | 0.78 | FFAR1 (0.54) | MRGPRX4PLA2G4BLTB4RLTB4R2CTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | claimed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| CN-101969773-A | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2011-02-09 | — | — | CN | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| CN-102976928-B | Compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2014-09-17 | — | — | CN | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| CN-102976928-A | Compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2013-03-20 | — | — | CN | disclosed |
| CN-101969773-A | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2011-02-09 | — | — | CN | disclosed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | SLC22A12 139/4885MRGPRX4 1727/4885GAA 3963/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | SLC22A12 257/4885MRGPRX4 1966/4885GAA 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.